<DOC>
	<DOCNO>NCT01382966</DOCNO>
	<brief_summary>Sclerostin , product SOST gene , locate chromosome 17 , locus q11.2 human , originally believe non-classical Bone morphogenetic protein ( BMP ) antagonist.Sclerostin recently identify component parathyroid hormone ( PTH ) signal transduction . Chronic kidney disease ( CKD ) associate abnormality bone mineral metabolism.New advance pathogenesis renal osteodystrophy ( ROD ) change perspective many feature treatment view . Calcium , phosphate , parathyroid hormone ( PTH ) , vitamin D show important determinant survival associate kidney disease . Now ROD dependent independent factor link survival skeletal frailty.Furthermore , ROD show underappreciated factor level serum phosphorus CKD . The discovery elucidation mechanism hyperphosphatemia cardiovascular risk CKD change view ROD . Emerging current data suggests promise role serum measurement sclerostin addition iPTH diagnosis high bone turnover chronic kidney disease-5D patient ( dialysis patient ) . Because close relationship ROD cardiovascular disease , aim study investigate association sclerostin , arteriovenous fistula thrombosis , echocardiography carpal tunnel syndrome maintenance hemodialysis patient .</brief_summary>
	<brief_title>Serum Sclerostin Levels , Cardiovascular Parameters Carpal Tunnel Syndrome Maintenance Hemodialysis Patients</brief_title>
	<detailed_description>Sclerostin , product SOST gene , locate chromosome 17 , locus q11.2 human , originally believe non-classical Bone morphogenetic protein ( BMP ) antagonist.More recently Sclerostin identify bind LRP5/6 receptor inhibit Wnt signal pathway .Wnt activation circumstance antagonistic bone formation . Although underlying mechanism unclear , believe antagonism BMP-induced bone formation sclerostin mediate Wnt signalling , BMP signal pathway . Sclerostin produce osteocyte catabolic effect bone formation . This protein , length 113 residue , dssp secondary structure 28 % beta sheet ( 6 strand ; 32 residue . Sclerostin inhibitory effect lifetime osteoblast . Sclerostin production osteocyte inhibit parathyroid hormone , mechanical loading cytokine include oncostatin M , cardiotrophin-1 leukemia inhibitory factor . Sclerostin production increase calcitonin . Thus , osteoblast activity self regulate negative feedback system.Sclerostin recently identify component parathyroid hormone ( PTH ) signal transduction . Chronic kidney disease ( CKD ) associate abnormality bone mineral metabolism.Renal osteodystrophy ( ROD ) one three component chronic kidney disease-mineral bone disorder ( CKD-MBD . Patients CKD may develop various type bone disease , span spectrum extreme situation severe osteitis fibrosa , osteomalacia , mixed osteopathy , adynamic bone disease . In addition , patient may osteoporosis , increase risk fracture , advance less severe CKD stage ( 2- 4 ) , , turn , result excess mortality New advance pathogenesis renal osteodystrophy ( ROD ) change perspective many feature treatment view . Calcium , phosphate , parathyroid hormone ( PTH ) , vitamin D show important determinant survival associate kidney disease . Now ROD dependent independent factor link survival skeletal frailty.Furthermore , ROD show underappreciated factor level serum phosphorus CKD . The discovery elucidation mechanism hyperphosphatemia cardiovascular risk CKD change view ROD . Emerging current data suggests promise role serum measurement sclerostin addition iPTH diagnosis high bone turnover chronic kidney disease-5D patient ( dialysis patient ) . The demonstration level serum sclerostin , directly produce osteocyte , good predictor bone formation patient CKD may clinical interest.Because close relationship ROD cardiovascular disease , aim study investigate association sclerostin , arteriovenous fistula thrombosis , echocardiography carpal tunnel syndrome maintenance hemodialysis patient .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Carpal Tunnel Syndrome</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Renal Osteodystrophy</mesh_term>
	<criteria>Maintenance hemodialysis patient ( minimum 6 month duration ) Willingness Age &gt; 18 year Infection Malignancy Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>sclerostin</keyword>
	<keyword>arteriovenous fistula thrombosis</keyword>
	<keyword>carpal tunnel syndrome</keyword>
	<keyword>echocardiography</keyword>
</DOC>